Postgraduate Research Student
Burcu Kilic
Thesis title:
Boosting Pharmaceutical Innovation in the Post-TRIPS Era; The Real-Life Lessons for the Developing World
Supervisors:
Biography
Burcu Kilic received a LLB degree from Ankara University, Turkey with first class honours in 2002. She was admitted to the Ankara Bar in 2003. She practiced law as an associate lawyer in private practice until 2005. In 2005, she was awarded British Chevening Scholarship to undertake postgraduate law degree in the UK and she received a LLM degree in Intellectual Property Law from Queen Mary, University of London in 2006.
She was awarded the Swedish Institute Scholarship in 2006 and completed the Master Programme in Law and Information Technology, at Stockholm University, Sweden in 2007. Following her studies in Sweden, she was awarded full studentship from the School of Law, Queen Mary, University of London for her doctoral research.
She has been working on her doctoral research since 2007. During her doctoral research, she has received numerous awards and honours including the research grant from the Central Research Fund, University of London, in order to conduct fieldwork essential to her research.
Research
Burcu’s research is focusing on pharmaceutical innovation in the Post-TRIPS period. The research undertaken over the course of the doctoral thesis investigates the concept of ‘innovation’ and identifies the key issues, which are key to reviving the local industries through innovation. It gives an account of the innovation practices from all around the world. The thesis also illustrates the crucial role that patent strategies play within processes of pharmaceutical innovation. Basing on an understanding of the post-TRIPS environment and the innovation good practices, the thesis specifically addresses to what extent the lessons from other countries’ experiences can be transferred to current policy developments for innovation in the pharmaceutical industry.
Overall, the research findings aim to contribute to the body of knowledge in relation to new policies that can promote innovation and ensure the sustainability of the pharmaceutical industry in developing countries.
